RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
NCT06149494
COPD, COPD Exacerbation Acute
London, United Kingdom
View Trial DetailsNCT Number: NCT02753556
ScreenFlow is a chronic obstructive pulmonary disease (COPD) screening tool currently being studied and iteratively developed that incorporates a questionnaire administered on a tablet and data from a digital peak flow meter to calculate a risk score to identify the risk of developing moderate-to-severe COPD for the participant. The purpose of this study is to assess the usability of ScreenFlow deployed as a free-standing kiosk and observe where users encounter trouble navigating the system. The kiosk will be situated in a public area of a hospital where passersby can approach and fill out a ScreenFlow survey if they meet the eligibility criteria. A subset of participants will be asked to participate in a follow-up questionnaire about their experience using the system and about any follow-up action they may have taken caused by their results from the ScreenFlow screening.
Looking for future studies?
Notify Me40 year and older
All sexes
Observational
This is a cross-sectional study to determine the usability of ScreenFlow deployed as a kiosk. As such, everyone who uses ScreenFlow will be asked to complete a brief questionnaire on its features including visual appeal and ease of use. Additionally, a subset of 36 subjects whose estimated ScreenFlow risk of moderate-to-severe COPD is high will be asked to participate in a follow up phone questionnaire to ascertain, a) whether screening results were discussed with the subjects' health provider, b) impact of the ScreenFlow results on health behavior, c) whether the individual shared the ScreenFlow result with his/her health provider (or intention to share the result), and d) any action that may have been taken by the medical provider after the provider received the report.
The ScreenFlow platform will be available in a common area of Boston Medical Center over the course of six weeks, under the supervision of a study staff member. The platform will be available to the public during regular business hours from Monday to Friday. Subjects will complete a ScreenFlow screening by answering some questions, watching a video and performing peak flow measurement as instructed in the video. They will be given a report of the ScreenFlow result indicating whether there is a high probability of having moderate to severe COPD. Over six weeks, approximately 3600 patients should come in contact with the kiosk. Conservatively, we estimate that if 10% of them use it, we will have 360 users, of which 10% may have a high risk score on screening. This will give the desired sample size of 36 patients for the phone based follow-up interview.
Thirty-six subjects will give their feedback through a phone based follow-up interview with a study staff member to assess how ScreenFlow may have influenced their subsequent medical care. We will consent 36 subjects for these follow-up calls, with the expectation that some may be difficult to reach or may decline to participate in the follow-up call.
In the interview we will ask whether the participants discussed COPD with their primary care providers, and the extent to which their care may have been influenced by this screening result. For those who have not had the opportunity to share results with their provider by the time of the follow-up call, we will ask about the effect of the positive screening result on their perception of COPD risk, intention to notify their provider, and health behavior.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Six weeks
Out of the entirety of screening results for all participants that use the ScreenFlow system during the study, calculation of the proportion of "positive" screens
Time frame: Six weeks
Each participant that uses the ScreenFlow system will be asked to complete a qualitative survey upon completion of the ScreenFlow questionnaire. The survey will focus on the user experience and usability of the ScreenFlow system.
Time frame: Six weeks
During each session a participant completes using the ScreenFlow system, we will track each touch on the tablet screen, including the time it takes for a user to make each touch. This will provide input into questions that may be confusing to users, and interface designs that may not be intuitive.
Time frame: Six weeks
We will track the number of adults that are "exposed" wherein they pass by or see the ScreenFlow kiosk, and also keep track of how many "exposed" adult then opt to approach and use the system.
Dimagi Inc.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06149494
COPD, COPD Exacerbation Acute
London, United Kingdom
View Trial DetailsNCT04930666
Chronic Disease, Disease Attributes
New York, United States
View Trial DetailsNCT03721952
Brain Diseases, Brain Injuries
Seattle, Washington, United States
View Trial DetailsNCT05241288
Bronchial Diseases, Chronic Disease
Chapel Hill, North Carolina, United States
View Trial Details